OR WAIT null SECS
September 27, 2023
Two months after tornado strikes North Carolina facility, manufacturing will undergo a phased approach, with full capacity expected by the end of 2023.
September 25, 2023
CDMO purchases branded sachet-packaging machine for commercial manufacturing.
The insulated shipping containers can be used in the pharma industry and are reportedly environmentally friendly.
September 22, 2023
Deal to focus on development and commercialization in key emerging countries.
September 21, 2023
Deal aims to provide diabetes treatment to patients across the continent.
September 19, 2023
SaaS’ branded platform expected to help grow manufacturer’s therapeutic development processes.
CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.
The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.
September 14, 2023
Financial commitment is intended to benefit development and commercialization of new products.
September 13, 2023
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.